Abstract
Background24-week data from ACT-RAY comparing an add-on strategy (TCZ+MTX) with a switch strategy (TCZ+placebo [PBO]) in MTX-IR patients have been previously reported, demonstrating relevant clinical and radiographic benefit without a...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have